Jane Street Group LLC Cuts Holdings in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX)

Jane Street Group LLC reduced its position in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) by 50.6% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 119,901 shares of the company’s stock after selling 123,054 shares during the period. Jane Street Group LLC owned 0.06% of Lineage Cell Therapeutics worth $109,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the company. SG Americas Securities LLC bought a new stake in shares of Lineage Cell Therapeutics in the 3rd quarter worth about $46,000. XTX Topco Ltd purchased a new position in Lineage Cell Therapeutics in the second quarter worth about $61,000. GSA Capital Partners LLP purchased a new position in Lineage Cell Therapeutics in the third quarter worth about $84,000. Rhumbline Advisers increased its stake in Lineage Cell Therapeutics by 15.1% during the second quarter. Rhumbline Advisers now owns 132,491 shares of the company’s stock worth $132,000 after acquiring an additional 17,411 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its position in Lineage Cell Therapeutics by 35.7% during the second quarter. Bank of New York Mellon Corp now owns 435,958 shares of the company’s stock valued at $435,000 after purchasing an additional 114,762 shares during the period. 62.47% of the stock is currently owned by hedge funds and other institutional investors.

Lineage Cell Therapeutics Stock Performance

NYSEAMERICAN LCTX opened at $0.55 on Wednesday. The firm has a market capitalization of $121.23 million, a price-to-earnings ratio of -4.58 and a beta of 1.16. Lineage Cell Therapeutics, Inc. has a 12-month low of $0.48 and a 12-month high of $1.61.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the stock. Maxim Group dropped their price target on shares of Lineage Cell Therapeutics from $5.00 to $3.00 and set a “buy” rating for the company in a research note on Friday, January 10th. HC Wainwright boosted their target price on Lineage Cell Therapeutics from $7.00 to $9.00 and gave the company a “buy” rating in a research report on Wednesday, December 4th. Finally, D. Boral Capital reaffirmed a “buy” rating and set a $2.00 target price on shares of Lineage Cell Therapeutics in a research note on Friday, January 3rd. Five analysts have rated the stock with a buy rating, According to MarketBeat, Lineage Cell Therapeutics presently has an average rating of “Buy” and an average price target of $4.80.

About Lineage Cell Therapeutics

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.